Skip to main content
< Back
About
About the conference
Latest updates
Organisers & Partners
App
Press room
Programme 19
Full programme
Tracks
Speakers 19
Keynote speakers
All speakers
Side events 19
Venue 19
About the venue
Location
Rooms
Subscribe
New psychoactive substances
Sessions
Plenary session
Poster session
Big debate
Structured session
Workshop
Oral presentation session
Short communication session
Poster guided tour
New psychoactive substances
New psychoactive substances — Basic science
New psychoactive substances — Youth
Thursday, 08 August
14:20
A mixed methods study to identify the implications for policy and practice
Variations and determinants of novel psychoactive substance use
14:20
Wednesday, 23 October
10:50
Insights in biology
10:50
to
12:20
Insights zone 1 (I1)
Fernando Rodriguez de Fonseca
13:20
European Research Area Network on Illicit Drugs
13:20
to
14:50
Insights zone 4 (I4)
Henk Garretsen
The challenges of monitoring new drugs
13:20
to
14:50
Insights zone 2 (I2)
Ana Gallegos
15:00
New psychoactive substances
15:00
to
16:30
Networking zone 3 (N3)
Pierluigi Simonato
16:50
Towards a public health approach
An epidemiological overview of new psychoactive substances use in Europe
16:50
to
18:20
Central square 3 (C3)
Margriet van Laar
Thursday, 24 October
10:50
Methods and approaches to inform drug policy and practice
10:50
to
12:20
Networking zone 4 (N4)
Márya Hynes
15:00
Drug markets
15:00
to
16:30
Insights zone 4 (I4)
Dirk Korf
16:50
Trends and harms related to recreational drugs, prescription medicines and new psychoactive substances
European Drug Emergency Network Plus (Euro-DEN Plus)
16:50
to
18:20
Main stage
Nicola Singleton
18:30
Software-automated approach to monitoring online e-shops offering new psychoactive substances
18:30
to
19:30
Futures zone 3 (F3)
Vendula Belackova
Martin Pazitny
Opioids — current and emerging lessons
18:30
to
19:30
Networking zone 4 (N4)
Roumen Sedefov
Nightlife, festivals and other recreational settings
18:30
to
19:30
Networking zone 3 (N3)
Andrew Bennet
Friday, 25 October
09:00
Contemporary issues in addictions
09:00
to
10:30
Central square 3 (C3)
Henk Garretsen
10:45
Monitoring drug trends in the EU and Australia using digital and online instruments
10:45
to
12:15
Futures zone 1 (F1)
Matthijs Blankers
Presentations
Plenary session
Poster session
Big debate
Structured session
Workshop
Oral presentation session
Short communication session
Poster guided tour
Wednesday, 23 October
11:00
Oral presentation
Blunted ventral striatal responses to anticipated rewards foreshadow problematic drug use in novelty-seeking adolescents
11:00
to
11:15
Insights zone 1 (I1)
Christian Büchel
11:15
Oral presentation
Epigenetics of drug addiction: a therapeutic opportunity and a transgenerational inheritance concern
11:15
to
11:30
Insights zone 1 (I1)
Felix Carvalho
11:30
Oral presentation
An astrocyte-microglia crosstalk mediating neuroinflammation under exposure to psychostimulants
11:30
to
11:45
Insights zone 1 (I1)
Teresa Summavielle
11:45
Oral presentation
Acute psychotropic effects of 9-tetrahydrocannabinol (THC) associated with resting state brain function in the human insula: a pharmacological MRI study
11:45
to
12:00
Insights zone 1 (I1)
Matthijs Bossong
12:00
Oral presentation
Synthetic cannabinoids 5F-PB22 and THJ-2201 promote neuronal differentiation in neureblastoma cells at biologically relevant concentrations
12:00
to
12:15
Insights zone 1 (I1)
João Pedro Silva
13:25
Oral presentation
Alama-nightlife: Understanding the dynamics and consequences of young adult substance use pathways, a longitudinal and momentary analysis in the European nightlife scene
13:25
to
13:40
Insights zone 4 (I4)
Margriet van Laar
13:30
Oral presentation
The advantages and challenges of developing a national earlier warning system - Transforming Bergen Earlier Warning System (BEWS) into Norwegian National Earlier Warning System (NNEWS).
13:30
to
13:45
Insights zone 2 (I2)
Else Kristin Utne Berg
13:40
Oral presentation
Understanding the interplay between cultural, biological and subjective factors in drug use pathways
13:40
to
13:55
Insights zone 4 (I4)
Reinout Wiers
13:45
Oral presentation
New psychoactive substances in Portugal
13:45
to
14:00
Insights zone 2 (I2)
Ludmila Carapinha
13:55
Oral presentation
ATTUNE: Stimulant users in Europe - a state of the art project, reporting on findings and findings to expect
13:55
to
14:10
Insights zone 4 (I4)
Uwe Verthein
14:00
Oral presentation
Recent use of synthetic cannabinoids, synthetic opioids and other psychoactive drug groups among high-risk drug users in Israel.
14:00
to
14:15
Insights zone 2 (I2)
Barak Shapira
14:10
Oral presentation
Sensory processing sensitivity and drug use recovery pathways
14:10
to
14:25
Insights zone 4 (I4)
Judith Homberg
14:15
Oral presentation
Use of physiologically based pharmacokinetic modelling of new psychoactive substances
14:15
to
14:30
Insights zone 2 (I2)
Nuno Elvas Silva
14:25
Oral presentation
Pathways to addiction recovery: mechanisms of change in the UK, Belgium and the Netherlands
14:25
to
14:40
Insights zone 4 (I4)
David Best
14:30
Oral presentation
Combining monitoring data to evaluate responses to NPS: the case of 4-FA in the Netherlands
14:30
to
14:45
Insights zone 2 (I2)
Margriet van Laar
14:40
Oral presentation
Illicit drug policies and social outcomes: a cross-country analysis
14:40
to
14:50
Insights zone 4 (I4)
Ricardo Gonçalves
15:10
Short communication
Insights into benzo fury toxicity: 5-(2-aminopropyl)benzofuran and 6-(2-aminopropyl)benzofuran disrupt oxidative, energetic and mitochondrial homeostasis of hepatocytes in vitro
15:10
to
15:20
Networking zone 3 (N3)
Rita Roque Bravo
15:20
Short communication
Tracking NPS in Portugal: the case of MTMP
15:20
to
15:30
Networking zone 3 (N3)
Helena Gaspar
15:30
Short communication
Single binge dosing of 4-Methylethcathinone (4-MEC) induces sturdy and durable cognitive impairment in mice
15:30
to
15:40
Networking zone 3 (N3)
Cristina Sampayo
15:40
Short communication
Abuse potential of new psychoactive substances: N-ethylhexedrone, 4-Methylethcathinone, 4-Fluoromethcathinone and Buphedrone
15:40
to
15:50
Networking zone 3 (N3)
Cristina Sampayo
15:50
Short communication
Studies on the metabolism of synthetic cathinones N-ethylhexedrone and buphedrone using liquid chromatography-mass spectrometry (LC-MS/MS)
15:50
to
16:00
Networking zone 3 (N3)
Joana Carrola
16:00
Short communication
Changa – fist time identification in Portugal
16:00
to
16:10
Networking zone 3 (N3)
Maria João Caldeira
16:10
Short communication
Variations and determinants of novel psychoactive substance use: a mixed methods study to identify the implications for policy and practice
16:10
to
16:20
Networking zone 3 (N3)
Kathryn Higgins
16:50
Oral presentation
Prevalence and patterns of NPS use in general and school European populations
16:50
to
18:20
Central square 3 (C3)
Julian Vicente
Oral presentation
NPS use in self-selected respondents of the population (EU web-survey)
16:50
to
18:20
Central square 3 (C3)
Julian Vicente
Oral presentation
Assessing patterns of use of new psychoactive substances (NPS) – the NPS Euronet project
16:50
to
18:20
Central square 3 (C3)
Noelia Salgueiro-González
Oral presentation
Drug trends at UK festivals and self-reported information and treatment needs by people who use NPS
16:50
to
18:20
Central square 3 (C3)
Katy MacLeod
Oral presentation
New psychoactive substance use among marginalised and high risk populations in Europe
16:50
to
18:20
Central square 3 (C3)
Jane Mounteney
Thursday, 24 October
11:00
Short communication
Quantitative and qualitative evidences for better gender-based prevention of adolescent addictive behaviours, with and without substance
11:00
to
11:10
Networking zone 4 (N4)
Patricia Gómez
11:10
Short communication
The European Web Survey on Drugs: patterns of use of new psychoactive substances in Belgium
11:10
to
11:20
Networking zone 4 (N4)
Lies Gremeaux
11:20
Short communication
From chronology to processes: combining biographical interview with episodic analysis in a life story
11:20
to
11:30
Networking zone 4 (N4)
Isabel María Herrera-Sánchez
11:30
Short communication
Coding multiple drug use in ICD-10 and ICD-11
11:30
to
11:40
Networking zone 4 (N4)
Espen Walderhaug
11:40
Short communication
The scientific portrayal of decriminalisation models for psychoactive substances: a scoping review
11:40
to
11:50
Networking zone 4 (N4)
Isabel María Herrera-Sánchez
Short communication
The scientific portrayal of decriminalisation models for psychoactive substances: a scoping review
11:40
to
11:50
Networking zone 4 (N4)
Daniela Filipa Ferreira
11:50
Short communication
The role of the juveniles in the structure and dynamics of the illegal drug market in the Republic of Croatia
11:50
to
12:00
Networking zone 4 (N4)
12:00
Short communication
Lifetime prevalence of drug use before imprisonment in Europe: results from a systematic literature review
12:00
to
12:10
Networking zone 4 (N4)
12:10
Short communication
Public participation in effective development of a regional drug strategy: experiences from the South East region of Ireland
12:10
to
12:20
Networking zone 4 (N4)
Michelle Foley
15:10
Oral presentation
Purity, adulteration and price of drugs bought on-line versus off-line in the Netherlands
15:10
to
15:25
Insights zone 4 (I4)
Daan van der Gouwe
15:40
Oral presentation
A descriptive analysis of the illicit supply of new psychoactive substances within and from China
15:40
to
15:55
Insights zone 4 (I4)
Minqi Zhao
15:55
Oral presentation
MDMA dosage in XTC tablets: size matters
15:55
to
16:10
Insights zone 4 (I4)
Ruben Vrolijk
16:10
Oral presentation
Understanding drug markets: results of the MARSTUP study
16:10
to
16:25
Insights zone 4 (I4)
Frank Zobel
17:00
Oral presentation
The European Drug Emergencies Network Plus (Euro-DEN Plus) project: what has it shown us over the last 5 years?
17:00
to
17:15
Main stage
Isabelle Giraudon
17:15
Oral presentation
Prescription medicine misuse and related acute toxicity
17:15
to
17:30
Main stage
Alison Dines
17:30
Oral presentation
Comparison of the acute harms of the synthetic cannabinoids and cannabis
17:30
to
17:45
Main stage
Christopher Yates
17:45
Oral presentation
Clinical coding of acute drug and NPS presentations: why doesn’t it work and what can be done
17:45
to
18:00
Main stage
David Wood
18:40
Short communication
Opioid-related problems in Baltic States and Poland: has the turning point come?
18:40
to
18:50
Networking zone 4 (N4)
Katri Abel-Ollo
Short communication
Recommendations for NPS-targeted initiatives in Belgium
18:40
to
18:50
Networking zone 3 (N3)
Anton van Dijck
18:50
Short communication
Estonia’s fentanyl battle: time to scale-up overdose prevention strategy?
18:50
to
19:00
Networking zone 4 (N4)
Sibella Hare Breidahl
Short communication
Predicting the onset of ketamine use among frequent nightlife attendees
18:50
to
19:00
Networking zone 3 (N3)
Charlotte van Miltenburg
19:00
Short communication
Assessment of possibilities for raising the quality of health care provided to opioid users by increasing access to substitution treatment
19:00
to
19:10
Networking zone 4 (N4)
Boguslawa Bukowska
Short communication
Why a zero tolerance drug policy for festivals is not working (well)
19:00
to
19:10
Networking zone 3 (N3)
Jochen Schrooten
19:10
Short communication
Rising incidence of ageing opioid users within the EU wide treatment
19:10
to
19:20
Networking zone 4 (N4)
Anne Marie Carew
Short communication
Towards gender-sensitive responses in the drugs field: Intersections between sexual violence, drug use in nightlife environments
19:10
to
19:20
Networking zone 3 (N3)
Cristiana Vale Pires
19:20
Short communication
Setting up a HPLC in a 7-day psychedelic music festival: drug checking moving forward
19:20
to
19:30
Networking zone 3 (N3)
Daniel Martins
Short communication
The neglected public health problem of opioid use among offenders - why we have failed and where we can improve.
19:20
to
19:30
Networking zone 4 (N4)
Friday, 25 October
09:15
Oral presentation
Assessing the impact of laws controlling the online availability of 25I-NBOMe, AH-7921, MDPV and MXE – outcomes of a semi-automated e-shop monitoring. Drugs: education, prevention and policy
09:15
to
09:30
Central square 3 (C3)
Vendula Belackova
09:30
Oral presentation
Some constitutional issues regarding control of new psychoactive substances
09:30
to
09:45
Central square 3 (C3)
Krzysztof Krajewski
09:45
Oral presentation
Making the National Strategy on Addiction work for practitioners in addiction aid: how Swiss authorities and civil society bridge theory and practice
09:45
to
10:00
Central square 3 (C3)
Mirjam Weber
10:00
Oral presentation
Leveraging citizen science and the power of civil society networks in a trans European mobile application
10:00
to
10:15
Central square 3 (C3)
Florian Scheibein
10:45
Oral presentation
Development and contribution to software to monitor online discussions on internet drug discussion forums
10:45
to
12:15
Futures zone 1 (F1)
Magali Martinez
Oral presentation
Trends in the online availability of fentanyl (analogues) in Australia and the impact of policy interventions (2012-2019)
10:45
to
12:15
Futures zone 1 (F1)
Amy Peacock
Oral presentation
Routine internet forum monitoring for new psychoactive substances: implementation of the EC funded I-TREND project results
10:45
to
12:15
Futures zone 1 (F1)
Daan van der Gouwe
Oral presentation
Automated monitoring of online shops offering new psychoactive substances in the EU
10:45
to
12:15
Futures zone 1 (F1)
Martin Pazitny
Vendula Belackova
Oral presentation
4-Fluoramphetamine in the Netherlands: Text-mining and sentiment analysis of internet drug discussion forums
10:45
to
12:15
Futures zone 1 (F1)
Matthijs Blankers